NCT07178652Not yet recruiting
Preeclampsia and Defective Placentation in Oocyte Donation: Importance of HLA-C and KIR
Source: ClinicalTrials.gov · Last updated 17 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The IMMUN-OR study aims to study HLA-C/KIR combinations when looking at the risk of development of preeclampsia (PE) in pregnancies after oocyte donation. With the use of oocyte donation currently on the rise, the importance of identifying risk factors for the higher frequency of PE development is clear. Certain HLA-C/KIR combinations have already been linked to higher risk of obstetric complications. This study will look at these combinations within the specific situation of oocyte donation. This will further investigate the importance of the immunological interface when looking at PE. Participants will be chosen from a database of all the live births after oocyte donation at our center. The research team will contact the mother, child and donor. If all three agree to participate, they will be invited to our center, where the research team will take a cheek swab. This swab will then be used to isolate a DNA sample. With these samples, we can determine the HLA-C/KIR combination for each threesome. When all samples have been collected, two groups are made based off their health outcome: one group that did develop PE during their pregnancy, and one group that did not develop PE. The different HLA-C/KIR combinations will be compared, and the research team will look to discover if one combination is linked to a higher occurrence of PE development.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 2325 (estimated)
- First submitted
- 2 Sept 2025
- Start date
- 1 Sept 2025
- Primary completion date
- 31 Dec 2026
- Lead sponsor
- Universitair Ziekenhuis Brussel
- NCT number
- NCT07178652
What you commit to
- Study type: Observational
- Planned participants: 2325
- From 1 Sept 2025 to the primary completion date, 31 Dec 2026
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Unknown HLA-C/KIR typing of acceptor, donor or offspring (resumlts of all 3 parties must be present to participate.
Who the study is looking for
- Every live birth delivery post oocyte donation (mother, child, donor).
Sex: Female · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.